dallas glp-1 lawsuit DallasLatesNews: is projected to exceed its employee health plan budget by $17 million after expecting to save $12 million, largely due to a 69% increase in spending on weight-loss drugs Ozempic® NAION Lawsuit | Attorneys
Description
Tschp M, Nogueiras R, Ahrn B

Aesthetic Surg J

The primary action of GLP-1 receptor agonists is to increase insulin production in response to high blood sugar levels

Legislative authorization for the wildly popular program lapsed in late 2024, and although its direct impact had been blunted due to language permitting FDA to award PRVs until September 30, 2026 so long as the underlying products had received RPD designations before December 20, 2024, uncertainty over the programs fate was beginning to weigh on product developers and investors alike

Handling Editor: Hugh C Hemmings Jr Footnotes Co-sponsored and endorsed by the American Association of Clinical Endocrinology (AACE)

This benefit may be related to the effects of the drug and the weight loss it promotes